Lazard Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-148
| Closed | – | – | 2446 |
|
|
2024
Q4 | $0 | Hold |
148
| – | – | ﹤0.01% | 2419 |
|
|
2024
Q3 | $0 | Sell |
148
-255
| -63% | – | ﹤0.01% | 2373 |
|
|
2024
Q2 | $0 | Sell |
403
-5,656
| -93% | – | ﹤0.01% | 2346 |
|
|
2024
Q1 | $8K | Sell |
6,059
-3,356
| -36% | -$4.43K | ﹤0.01% | 1882 |
|
|
2023
Q4 | $10K | Buy |
9,415
+578
| +7% | +$614 | ﹤0.01% | 2097 |
|
|
2023
Q3 | $10K | Buy |
8,837
+457
| +5% | +$517 | ﹤0.01% | 2143 |
|
|
2023
Q2 | $11K | Buy |
8,380
+314
| +4% | +$412 | ﹤0.01% | 2176 |
|
|
2023
Q1 | $11K | Sell |
8,066
-76,575
| -90% | -$104K | ﹤0.01% | 2119 |
|
|
2022
Q4 | $98K | Buy |
84,641
+6,667
| +9% | +$7.72K | ﹤0.01% | 1543 |
|
|
2022
Q3 | $88K | Buy |
+77,974
| New | +$88K | ﹤0.01% | 1519 |
|
|
2022
Q1 | – | Sell |
-21,610
| Closed | -$52K | – | 2444 |
|
|
2021
Q4 | $52K | Buy |
+21,610
| New | +$52K | ﹤0.01% | 1723 |
|